HONG KONG – A consortium of Chinese investors will acquire a 90 percent stake in innovative oncology treatment developer Group NMS Co. Ltd., of Milan, Italy. The total value of the deal, including equity injection and debt restructuring, is around €300 million (US$361.25 million).